KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Debt to Equity: 2009-2016

Historic Debt to Equity for Vertex Pharmaceuticals (VRTX) over the last 3 years, with Dec 2016 value amounting to $0.22.

  • Vertex Pharmaceuticals' Debt to Equity fell 16.94% to $0.22 in Q4 2016 from the same period last year, while for Dec 2016 it was $0.22, marking a year-over-year decrease of 16.94%. This contributed to the annual value of $0.22 for FY2016, which is 16.94% down from last year.
  • Vertex Pharmaceuticals' Debt to Equity amounted to $0.22 in Q4 2016, which was down 9.02% from $0.25 recorded in Q3 2016.
  • Vertex Pharmaceuticals' 5-year Debt to Equity high stood at $0.30 for Q1 2015, and its period low was $0.22 during Q4 2016.
  • In the last 3 years, Vertex Pharmaceuticals' Debt to Equity had a median value of $0.27 in 2014 and averaged $0.26.
  • In the last 5 years, Vertex Pharmaceuticals' Debt to Equity increased by 7.39% in 2015 and then fell by 16.94% in 2016.
  • Over the past 3 years, Vertex Pharmaceuticals' Debt to Equity (Quarterly) stood at $0.27 in 2014, then increased by 0.36% to $0.27 in 2015, then dropped by 16.94% to $0.22 in 2016.
  • Its last three reported values are $0.22 in Q4 2016, $0.25 for Q3 2016, and $0.25 during Q2 2016.